[Effects of miR-424 on Proliferation and Migration Abilities in Non-small Cell Lung Cancer A549 Cells and Its Molecular Mechanism].
BACKGROUND
The inhibitory ability of miR-424 on the proliferation of renal carcinoma cell and the migration and invasion of cancer cells has been widely explored and demonstrated. However, the effects of miR-424 on non-small cell lung cancer (NSCLC) have not been systematically examined. In this study, detected the growth and invasion effect of miR-424 in NSCLC A549 cell. The migration and molecular mechanism of this cell are also detected.


METHODS
NSCLC A549 cell was transfected with miR-424 and its inhibitor. After transfection, the proliferation ability of A549 cell was detectedby CCK8 assay. Then, the migration ability in A549 cell was detected by migration assays. Furthermore, the expression level of MMP2 and MMP9 in A549 was detected by Western blot and immune fluorescence. The 3'UTR of E2F6 was cloned into luciferase reporter vector and its enzymatic activitywas detected to verify whether miR-424 can target E2F6. The expression level of E2F6 in a549 cell after transfecing with miR-424 was detected by Western blot.


RESULTS
After transfection of miR-424, the proliferation and migration abilities were remarkably decreased and the expression level of MMP-2 and MMP-9 were down-regulated in A549. Moreover, MiR-424 inhibited the enzymatic activity of luviferase reporter vector of E2F6. Specifically, the expression level of E2F6 was down-regulated in A549.


CONCLUSIONS
miR-424 can inhibit the proliferation and migration abilities of A549 by negatively regulating the expression of E2F6. .
Cancer Center, Medical Sciences Academy of Sichuan, Renming Hospital of Sichuan Province, Chengdu 610072, China.
Hongmin
H
Li
Cancer Center, Medical Sciences Academy of Sichuan, Renming Hospital of Sichuan Province, Chengdu 610072, China.
Haitao
H
Lan
Cancer Center, Medical Sciences Academy of Sichuan, Renming Hospital of Sichuan Province, Chengdu 610072, China.
Ming
M
Zhang
Cancer Center, Medical Sciences Academy of Sichuan, Renming Hospital of Sichuan Province, Chengdu 610072, China.
Ning
N
An
Cancer Center, Medical Sciences Academy of Sichuan, Renming Hospital of Sichuan Province, Chengdu 610072, China.
Ruilian
R
Yu
Cancer Center, Medical Sciences Academy of Sichuan, Renming Hospital of Sichuan Province, Chengdu 610072, China.
Yangke
Y
He
Department of Thoracic Surgery, Medical Sciences Academy of Sichuan, Renming Hospital of Sichuan Province, Chengdu 610072, China.
Chongzhi
C
Gan
D000072283:A549 Cells; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology*; D002465:Cell Movement; D049109:Cell Proliferation; D050701:E2F6 Transcription Factor / Q000235:genetics / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology*; D020778:Matrix Metalloproteinase 2 / Q000235:genetics / Q000378:metabolism; D020780:Matrix Metalloproteinase 9 / Q000235:genetics / Q000378:metabolism; D035683:MicroRNAs / Q000235:genetics / Q000378:metabolism*
D050701:E2F6 Transcription Factor; C491744:E2F6 protein, human; C554214:MIRN424 microrna, human; D035683:MicroRNAs; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9
Clin Respir J. 2015 Jan;9(1):27-33
24405893
Zhonghua Wei Chang Wai Ke Za Zhi. 2014 Jan;17(1):45-50
24519049
Zhongguo Fei Ai Za Zhi. 2013 Mar;16(3):157-61
23514946
Tumour Biol. 2015 Apr;36(4):3035-42
25501703
Pathol Oncol Res. 2013 Oct;19(4):739-48
23653113
Clinics (Sao Paulo). 2013 Jun;68(6):825-33
23778472
Blood. 2009 Oct 8;114(15):3255-64
19692702
Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004
14973191
Biomed Pharmacother. 2010 Jul;64(6):399-408
20363096
Lung Cancer. 2014 Mar;83(3):401-7
24491311
Cell. 2004 Jan 23;116(2):281-97
14744438
Oncol Lett. 2014 Jan;7(1):227-232
24348854